Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349, SHA:688505) expects its sales in the second quarter to be affected by cutting the price of some of its products.
The pharmaceutical company plans to reduce the price of its drug, doxorubicin hydrochloride liposome injection, by at least 35% lower than previous bidding prices, according to a Hong Kong Stock Exchange filing on Wednesday.
The reduction, which was in compliance with the rules and requirements of each province in China, was effective starting Thursday, May 1.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。